Rick Simpson Oil (RSO) in Champaign County: The Complete Evidence-Based Guide by OilWell Cannabis

If you’re reading this in Champaign County—whether you’re in Urbana, Champaign, Savoy, Mahomet, Rantoul, or anywhere across East Central Illinois—you’ve probably heard whispers about Rick Simpson Oil. Maybe you heard it from a fellow patient at Carle Foundation Hospital, a veteran at the VA clinic, or a friend caring for someone at OSF Heart of Mary. Maybe you’re a researcher at the University of Illinois Urbana-Champaign who stumbled across the term while investigating alternative therapies. Or maybe you’re dealing with chronic pain, cancer treatment side effects, PTSD, or insomnia, and you’re searching for something that actually works when prescriptions fall short.

We get it. We’ve been there. And we’re here to give you the most comprehensive, honest, science-backed RSO education available anywhere—serving Champaign County with the same integrity that’s made us Houston’s trusted cannabis authority since 2019.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began through personal suffering and a deep distrust of the medical system that failed him. For Champaign County residents who’ve felt let down by conventional medicine—whether you’re a farmer outside Tolono dealing with chronic pain from years of physical labor, a professor at UIUC navigating treatment-resistant insomnia, or a cancer patient at Carle exploring every option—Simpson’s story resonates because it mirrors the experience of being told “there’s nothing more we can do.”

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, prescribed medications either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused . Sound familiar? In Champaign County, where the opioid crisis has hit hard and many patients feel their doctors dismiss cannabis out of hand, this experience is unfortunately common.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference in Simpson’s advocacy, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up exists in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil .

Important context: Simpson’s account is personal testimony. The absence of clinical documentation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

The crusade — spreading the oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more .

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials, and framed his work as a grassroots challenge to pharmaceutical interests. Within cannabis communities, it was foundational—many people worldwide, including some in Champaign County’s early cannabis advocacy circles, first encountered RSO through this documentary .

Simpson’s advocacy brought him into conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and 2009, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad .

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, detailing his experience, oil-making process, and philosophical views .

Throughout his career, Simpson maintained that cannabis oil—particularly high-THC oil made his way—could cure cancer and many other diseases, and that pharmaceutical companies and government agencies were actively suppressing this knowledge .

Important context: Simpson’s conspiratorial framing is noted without endorsement. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core recommendation was consuming 60 grams of concentrated cannabis oil over approximately 90 days. This protocol was designed for cancer but recommended for many conditions .

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over roughly 90 days. Simpson considered this the minimum for serious cancer treatment.

Titration schedule

• Week 1: Begin with a dose the size of half a grain of dry rice—roughly 10-15 mg of oil—taken three times daily. Total daily intake: approximately 30-45 mg.
• Weeks 2-5: Double the dose approximately every four days to build THC tolerance gradually. By the end of this period—roughly 4-5 weeks—the target is approximately 1 gram (1,000 mg) of oil per day, divided into three doses.
• Weeks 5-12: Maintain approximately 1 gram per day, divided into three doses of roughly 333 mg each, until all 60 grams are consumed.

Administration methods

• Primary—oral: Place dose under tongue (sublingual) or swallow. Simpson considered oral ingestion most important for systemic absorption and internal cancers.
• Secondary—topical: For skin cancers, apply oil directly to lesions, cover with bandage, change every 3-4 days.
• Not primary—inhalation: Simpson acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained oral route was necessary for sustained, high-dose exposure.

Tolerance and psychoactive effects

• Simpson claimed patients develop significant THC tolerance within 3-4 weeks.
• He considered euphoric/sedating effects temporary and urged patients not to let the high discourage them.
• Recommended initial doses at night to sleep through early psychoactive effects.
• Advises avoiding driving or operating machinery during titration.

Post-protocol maintenance

After completing 60 grams, Simpson recommended 1-2 grams of oil per month indefinitely for long-term health and cancer prevention.

Dietary and lifestyle recommendations

Simpson advocated reducing sugar, avoiding processed foods, and improving nutrition, though this was secondary to the oil protocol.

Important context for evaluating this protocol

This protocol was designed by one person based on personal experience. Several critical points apply:

• No controlled trial validation. No published randomized controlled trials, cohort studies, or well-documented case series evaluate this 60-gram/90-day protocol for any cancer type or condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil daily. Assuming 60-90% THC content, this translates to approximately 600-900 mg of delta-9 THC per day—far exceeding anything studied clinically. For context, FDA-approved dronabinol is typically dosed at 2.5-20 mg per day.
• Real risks at these doses. Consuming 600-900 mg THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary treatment—potentially in place of proven therapies—introduces harm beyond the oil itself.

What is traditional Rick Simpson Oil — the product

Traditional RSO refers to the specific concentrated cannabis oil Simpson made. It was defined by his method and materials .

Source material

Simpson used high-THC, indica-dominant cannabis strains. He favored heavy, sedating indica genetics and generally recommended against sativa for cancer treatment. Starting material varied by availability and growing season—no strain standardization.

Extraction solvent

Simpson originally used naphtha—a petroleum-based solvent (lighter fluid, Varsol). He later endorsed 99% isopropyl alcohol as an alternative. He warned against butane or acetone. Neither naphtha nor isopropyl alcohol is food-grade, creating significant safety issues.

Extraction process

1. Place dry/semi-dry cannabis in container (typically bucket)
2. Cover with solvent, agitate several minutes to dissolve cannabinoids
3. Pour solvent through filter (cheesecloth) into collection vessel
4. Repeat with fresh solvent to extract remaining cannabinoids
5. Place combined solvent washes in rice cooker or open vessel
6. Evaporate solvent at relatively low heat (maintains temperature that evaporates solvent without significant cannabinoid degradation, but high enough to decarboxylate THCa and destroy most volatile terpenes)
7. Thick, dark oil remains at bottom
8. Transfer to oral syringes for storage/dosing

Appearance and physical characteristics

Traditional RSO was nearly black, thick, viscous, tar-like, with strong cannabis odor and possible solvent-residual smell. Sticky and difficult to handle at room temperature, more fluid when warmed.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. Heat converted essentially all THCa to delta-9 THC. Traditional RSO was activated, THC-dominant.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG the source strain contained were present at natural ratios—not controlled, measured, or targeted.
• No ratio control. Profile entirely determined by source plant genetics and growing conditions.
• Estimated THC content. Likely 60-90% total THC by weight, never lab-verified in traditional production.

Terpene content

Minimal to none. Solvent extraction and high-heat evaporation effectively stripped terpenes. Most cannabis terpenes volatilize at temperatures well below cannabinoid degradation thresholds.

Standardization and testing

None. Every batch differed based on starting material, growing conditions, solvent purity, extraction technique, evaporation temperature/duration, and maker’s process. Simpson operated before standardized lab-testing infrastructure. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening.

Residual solvent risk

Naphtha may contain benzene, toluene, other toxic/carcinogenic compounds. Incomplete solvent purging—difficult to verify without lab testing—leaves potentially harmful residues. Modern extraction uses food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s claims vs. the evidence record

Simpson claimed RSO could cure cancer and many other diseases. He was adamant and consistent throughout his advocacy career .

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted results to peer review. His evidence base consisted of personal experience, self-reported patient outcomes, and informal testimonials—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature exists and is scientifically interesting:

• In vitro studies show THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal models show some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings generate legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro/animal results and human clinical outcomes is vast.
• No human clinical trial has demonstrated that RSO or any cannabis oil cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory, small, and have not produced results supporting cancer-cure claims .

Institutional positions

• U.S. National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in lab and animal models but does not endorse cannabis or cannabis oil as cancer treatment .
• U.S. Food and Drug Administration (FDA): Has not approved any cannabis plant product for cancer treatment. Only FDA-approved cannabinoid-related products are Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada: Has never approved RSO or cannabis oil as cancer cure.
• NCCIH: States strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight-loss indications in HIV/AIDS—not cancer cure [1].

What Simpson got right

Simpson drew attention to cannabinoids as a serious biomedical research area when most of the world was ignoring or suppressing that conversation. His advocacy—however scientifically imprecise—helped create political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO remains the most recognized name for full-spectrum cannabis extract. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it’s not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative-medicine literature. Simpson’s absolute certainty about curative claims exceeded what the evidence could support then and still exceeds it today.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly and often loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract in syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .

Simpson has been critical of commercial products using the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that commercialization contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave oil away for free and urged people to make their own rather than buy from companies .

This philosophical tension is worth acknowledging. Simpson believed in DIY, free-access model where anyone could grow cannabis, extract oil, and treat themselves without corporate or governmental intermediaries. The modern cannabis industry has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depends on perspective, and the cannabis community remains divided.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain was grown. OilWell includes seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content. OilWell includes live terpenes at 5% with specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

• THCa as separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa to delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as distinct ingredient, preserving acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60-90% of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects broader cannabinoid research landscape rather than single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: oral oil in syringe. OilWell offers both 30 mL sublingual oil and 1-gram vape cartridge, each with format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Naphtha is complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic or carcinogenic compounds. Isopropyl alcohol, while cleaner, is also not intended for internal consumption. Incomplete solvent purging—very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of most straightforward improvements modern regulated cannabis industry has made over traditional RSO production model.

This evolution connects directly to product-quality discussion in GENERAL KNOWLEDGE section, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

The decarboxylation question

Traditional RSO was fully decarboxylated. Heat involved in evaporating solvent from rice cooker—typically sustained at or near solvent boiling point (naphtha ~60-80°C, isopropyl alcohol ~82°C)—was sufficient to convert essentially all THCa in extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over evaporation durations.

As result, acidic cannabinoids that exist abundantly in raw cannabis—THCa, CBDa, CBGa, others—were lost as distinct compounds in traditional RSO. Finished oil was decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as separate ingredient. This is intentional formulation choice informed by THCa evidence profile in GENERAL KNOWLEDGE section, which notes that THCa itself does not produce psychoactive effects associated with THC but that interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time [12].

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin volatilizing at temperatures between 21-157°C, with many most abundant terpenes—including myrcene, limonene, and pinene—having boiling points below 180°C. Traditional RSO production destroyed terpenes in two ways: first, by dissolving them into solvent wash along with cannabinoids; second, by evaporating them off during high-heat solvent-removal phase.

This meant traditional RSO was essentially cannabinoid-only product, despite being derived from terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5% with defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile discussed in GENERAL KNOWLEDGE section. Entourage-effect literature [20][29] provides theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence standards then and now

Rick Simpson operated in pre-legalization, pre-lab-testing era. When he began making and distributing oil in early 2000s, cannabis was illegal in Canada and most of world. No regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, no peer-reviewed journals dedicated to cannabis therapeutics. Cannabis underground was only access point, and personal experience was primary evidence currency.

Simpson’s methods reflected constraints of that era. His evidence was anecdotal. Production was unstandardized. Claims were untested in any formal sense. This is not necessarily moral failing—it is description of environment in which he operated.

This document takes fundamentally different approach. GENERAL KNOWLEDGE section applies formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. Intent is to honor historical origin of RSO while committing to standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison between Simpson’s dosing recommendations and dosing with modern, standardized, multi-cannabinoid formulation is not straightforward—products are fundamentally different.

Key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60-90% delta-9 THC. OilWell’s formula distributes 16,590 mg total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5%, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600-900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in entire 30 mL bottle (3 mg per mL), making per-dose delta-9 THC exposure dramatically lower.

Dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by per-compound evidence in GENERAL KNOWLEDGE section and responsible titration principles accounting for safety profile of each individual cannabinoid. This section does not provide specific dosing recommendations—that work requires its own development process and should incorporate safety considerations documented throughout this file.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and thriving retail sector, yet deeply affected by poverty and limited opportunities outside retail and healthcare. Reynosa is an industrial hub plagued by violence and cartel activity.

For Champaign County residents, this origin story gives OilWell a human foundation that transcends geography. Colin didn’t start from privilege—he started from a place more dangerous and difficult than most Champaign County residents can imagine. That authenticity matters. Many Champaign County readers, especially veterans, formerly incarcerated people, and those from high-violence communities, will recognize this experience without it needing to be their exact story.

Colin’s childhood in McAllen was marked by exposure to both opportunities and challenges of life along the border. Early on, he learned to hustle, taking on risky work transporting items across the border for various groups. Those experiences exposed him to complexities and dangers. A lot of his best friends have been killed or are in prison because of associated dangers. He has faced every form of violence imaginable, both in streets and across border. By sixteen, one way or another, he had to leave home for good.

Despite dangers, Colin did not fall into darkest paths like selling harder substances. Instead, he focused on cannabis, seeing it as safer and more beneficial alternative. He grew up in traditional cannabis world long before legalization, learning plant intimately while operating in shadows. Over time, he transitioned from early risky ventures to creating legal, legitimate business in industry he believes in.

Colin later became formally trained software engineer and did custom development work for Baylor College of Medicine, one of most prestigious medical institutions in Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—would eventually define OilWell’s approach.

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, companion who stood by Colin through toughest times. When Bentley fell seriously ill, veterinarians delivered verdict no pet owner wants: euthanasia was only humane option. Bentley was paralyzed in back legs. They said pain medications would destroy his internal organs, causing more pain and suffering. Choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not option. Colin had already faced too much loss and seen too much suffering. Bentley was fighter, just like him, and Colin was not ready to let him go. In desperate search for alternatives, he stumbled upon healing properties of CBD—through question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. Getting high. He had never explored therapeutic and medicinal applications. Jessica’s question exposed blind spot that would become mission.

Determined to save Bentley, Colin learned to create CBD golden paste—specialized cannabinoid formula for pets. It was not cure, but it was lifeline—and hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him ball to play. It was miracle. From paralyzed and facing euthanasia to fetching ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

For Champaign County pet owners—whether you’re in Urbana with your rescue dog, in Champaign with family cat, or out in county with farm animals—this story resonates deeply. Every pet owner understands that moment when conventional medicine says there’s nothing left, and you’d do anything for your companion.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

For Champaign County residents dealing with these same conditions—whether it’s a veteran with PTSD at the VA clinic, an elderly resident at Bement Health & Rehab, or a cancer patient at Carle dealing with chemotherapy side effects—this formulation knowledge is directly relevant.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—feat notoriously difficult and dangerous—using cannabinoid knowledge he developed keeping Bentley alive. The Peace Gummies formula that became OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers Peace Gummies formula in vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, discovery that cannabinoids work when pills do not.

For Champaign County residents dealing with addiction, PTSD, or severe anxiety—whether it’s a veteran from Chanute Air Force Base legacy, a first responder, or someone who has struggled with prescription dependence—this personal experience makes OilWell credible in way no corporate brand can be. Colin is his own case study. He doesn’t just sell cannabinoid products—he survives on them.

Over time, therapeutic benefits of cannabis that Colin first discovered through efforts to save Bentley became core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 recognition and Houston’s cannabis authority

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

While Champaign County is far from Houston geographically, this mainstream media validation from major-market ABC affiliate establishes credibility that transcends geography. When Champaign County residents research OilWell online, they’ll find this documented media track record that most local Illinois cannabis companies cannot claim. These features are independently produced, editorially controlled news segments from major affiliate that repeatedly identified Colin Valencia as most credible, quotable, and accessible voice in Houston’s legal cannabis industry. That’s recognition that cannot be purchased—it can only be earned.

Colin’s quote from first ABC13 feature in September 2019 captures OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

For Champaign County residents accustomed to University of Illinois research rigor and evidence-based decision-making, this commitment to honest education rather than hype is exactly what builds trust.

Current operations and commitment to quality

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). Company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced—they are carefully crafted with personal touch, from artwork on packaging to formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and builder’s mindset to company, but posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

For Champaign County customers, this means you’re getting products made by people who care deeply about quality and transparency, not mass-produced items from faceless corporation.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is formulated, multi-cannabinoid product informed by RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built product and distribution model that makes that accessible legally. For Champaign County residents who don’t qualify for Illinois medical cannabis program or don’t want to navigate bureaucracy, this is game-changer.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. Customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered product that puts that control in customer’s hands through chemistry rather than rhetoric.

3. Open-source formulas. OilWell publishes complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for modern cannabinoid marketplace by selling professionally manufactured product and publishing recipe.

4. Evidence-informed, not evidence-overstating. GENERAL KNOWLEDGE section in this document represents OilWell’s commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at federal level in United States. This legal framework is foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in entire 30 mL bottle—3 milligrams per milliliter—well under 0.3% threshold. All cannabinoids in formula are hemp-derived. Product is legal under federal law and in most states.

For Champaign County residents, this means you can legally order and possess this product without Illinois medical cannabis card. Illinois law aligns with Farm Bill for hemp-derived products, so you’re covered at both state and federal levels.

THCa—tetrahydrocannabinolic acid—is acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it has not been converted to delta-9 THC.

Practical significance is substantial. Customer can decarboxylate THCa into delta-9 THC at home by heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with existing 90 milligrams of delta-9 THC in formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving product psychoactive potency comparable to traditional illegal RSO, entirely at customer’s discretion after purchase.

This means same product can function as non-psychoactive anti-inflammatory (used raw) or as full-potency psychoactive cannabinoid product (after home decarboxylation). Customer controls decision. Product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions where hemp-derived products with less than 0.3% delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis (COAs), and receipts. For Champaign County residents, this means you have legal pathway to access product, but you accept responsibility for how you use it.

Open-source formulas—why OilWell publishes everything

OilWell publishes complete RSO formulas—every cannabinoid, every milligram amount, every percentage—in public documents including this one. RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

Rationale is straightforward: if someone cannot afford OilWell’s products—$129.99 for sublingual oil, $49.99 for vape cartridge—they can see exactly what formula contains, source individual cannabinoid distillates and isolates, and make their own version. Formulas are simultaneously product specifications, educational tools, and recipes for DIY makers.

This is direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented method. He never charged patients. OilWell adapted that ethos for modern cannabinoid marketplace: sell professionally manufactured, lab-tested, standardized product for those who want it, and publish complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

For Champaign County residents on fixed incomes, facing medical bills at Carle or OSF, or dealing with financial strain, this open-source approach means you’re not shut out. You have the recipe. That’s accessibility that respects your dignity.

Open-source philosophy did not start with RSO—it started with Bentley. On OilWell’s About Us page, Colin published actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing similar crisis could make it themselves:

CBD golden paste recipe for pets—the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on size and needs of pet; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and pepper. Stir until thoroughly mixed.
3. Cool and store in jar with lid. Refrigerate up to two weeks.
4. Add small amount of CBD oil to paste before giving to pet, adjusting dosage based on weight and health needs. Start low and increase gradually.

Serving suggestion: Mix small amount of paste with pet’s food once or twice daily. Monitor pet for changes and consult veterinarian if concerns arise. Always consult veterinarian before starting new supplement regimen.

This recipe—published for free, years before RSO formulas were open-sourced—demonstrates pattern is consistent. Colin gave away formula that saved Bentley before he gave away formula designed for people. Open-source ethos is not marketing strategy. It is foundational behavior of company.

The decarboxylation choice—patient-controlled potency

Traditional RSO was always fully decarboxylated. Heat of solvent evaporation converted all THCa into delta-9 THC, leaving patient with no choice about psychoactivity—oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1—Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. THCa evidence profile in GENERAL KNOWLEDGE section describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero psychoactive impairment. For Champaign County residents who need to function—whether you’re teaching at UIUC, working at Carle, farming outside Homer, or running business in Champaign—this is critical.

Option 2—Fully activated, home decarboxylation. Heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container converts 1,500 milligrams THCa into approximately 1,315 milligrams delta-9 THC. Combined with existing 90 milligrams delta-9 THC, this yields approximately 1,405 milligrams total delta-9 THC. Combined with 6,000 milligrams delta-8 THC, activated product achieves psychoactive potency comparable to traditional high-THC RSO—100% legally, because decarboxylation occurs at customer’s discretion after purchase. Customer may also transfer controlled portion from original bottle into second empty oven-safe glass container, decarboxylating only what they intend to use and preserving remainder in raw THCa form.

Option 3—Vape, auto-decarboxylation. RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is fastest-onset RSO delivery method available.

Conversion chemistry: THCa has molecular weight of 358.47 g/mol. Conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule during reaction.

This design puts potency decision entirely in customer’s hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than one-size-fits-all approach.

Solvent-free production

OilWell’s RSO is not extraction product in traditional sense. It is formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents present in finished product.

This approach eliminates residual solvent risk that is one of most significant safety concerns with traditional RSO production, as discussed in Rick Simpson section.

Product uses organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides neutral taste profile—significant improvement over tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through OilWell website. For Champaign County’s research-oriented residents, this transparency is exactly what builds trust.

The broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—OilWell’s most popular product. Carefully formulated experience designed to provide euphoric, long-lasting sensation. Particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. For Champaign County veterans dealing with trauma, this product has proven track record.

Peace Gummies—Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. Formula is also available in vape form for quick relief—Colin personally uses vape to manage his insomnia and severe PTSD on ongoing basis. For Champaign County residents tapering off benzos or dealing with severe anxiety, this is proven solution.

Custom creations—OilWell offers custom-made products tailored to specific needs of individual customers. Whether specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two product formats

OilWell offers RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

For Champaign County residents with active lifestyles—whether you’re working at University of Illinois, farming, or commuting to Springfield—this flexibility matters. You can use raw sublingual during day without impairment, then switch to decarbed or vape at night for sleep support.

Competitive comparison—OilWell RSO vs. alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products. These are based on publicly available specifications and presented for informational context.

OilWell RSO vs. Texas TCUP dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Same-day delivery Houston, nationwide and international shipping
Farm Bill compliant	No—state medical cannabis program	Yes—less than 0.3% delta-9 THC

For Champaign County residents, this comparison is crucial. Illinois has medical cannabis program, but qualifying conditions are restrictive, and you must travel to licensed dispensary. OilWell’s accessibility model means no medical card, no qualifying condition restrictions, direct shipping to your door in Champaign County.

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40-$50	$129.99

For Champaign County residents seeking serious cannabinoid therapy, the concentration difference is stark. OilWell delivers 16.5x total cannabinoids, with six additional cannabinoids beyond just CBD.

OilWell RSO vs. traditional illegal RSO—see Traditional RSO vs. modern formulated RSO table in Rick Simpson section above for full eleven-dimension comparison.

Condition-specific usage context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in GENERAL KNOWLEDGE section and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not substitute for professional medical care. These products have not been evaluated by Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult qualified healthcare provider before using cannabinoid products, especially if you have medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea/vomiting evidence [1][13], CBD anxiolytic buffering [3]

For Champaign County cancer patients at Carle Foundation Hospital or OSF Heart of Mary undergoing chemotherapy, this protocol addresses common side effects with evidence-based cannabinoid support.

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3-0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

For Champaign County residents dealing with chronic pain—whether from farming injuries, aging, or conditions like fibromyalgia—this offers daytime functionality with nighttime relief.

Sleep support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, delivers 50 mg CBN—dosage level investigated in 2024 sleep literature
• At 1.0 mL, delivers 25 mg CBN—above 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

For Champaign County residents struggling with insomnia—whether due to stress, pain, or other factors—this protocol provides researched dosing.

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

For Champaign County residents dealing with anxiety—whether from academic pressure at UIUC, work stress, or life challenges—this offers functional daytime support.

General titration principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and global accessibility

For Champaign County residents, this is the practical section that answers: “How do I actually get this product?”

OilWell operates only same-day RSO delivery system in Houston. Beyond Houston, company ships nationwide and internationally.

Houston same-day delivery (reference for completeness):

• Texas Medical Center: FREE, 2-4 hours
• Inner Loop (610): $5, 2-4 hours
• Within Beltway 8: $10, 3-5 hours
• Greater Houston suburbs: $15, 4-6 hours
• Extended region (60 miles): $20-25, same-day if ordered before 2 PM

Nationwide shipping to Champaign County

All 50 states where Farm Bill-compliant products are legal. For Champaign County, Illinois residents:

• USPS Priority Mail: 2-3 business days
• FedEx/UPS Ground: 3-5 business days
• Discreet packaging: No cannabis branding visible on exterior
• Tracking provided: For all orders
• Temperature-stable packaging: For summer shipments (important for Champaign County’s hot, humid summers)
• Signature-required option: Available for security

What you’ll receive:

• Full documentation including Certificates of Analysis (COAs)
• Receipts for your records
• Product packaged to maintain integrity during shipping from Houston to Central Illinois
• Instructions for use, decarboxylation, and storage

International shipping

OilWell ships internationally and has delivered to multiple countries across multiple continents. THCa legal framework makes this possible: because product contains less than 0.3% delta-9 THC at point of sale, it meets definition of hemp-derived product under 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

For Champaign County residents with family overseas or those who travel internationally, this access is unique. Rick Simpson could not ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Germany, chronic pain patient in Australia, or veteran in United Kingdom can now potentially access same clinical-strength multi-cannabinoid RSO formula that Houston resident receives via same-day delivery.

OilWell’s PANDEM1C SEO technology—proprietary system with 14 million distinct geopolitical locations in database and over 300 AI models—drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO in their own language.

How to order for Champaign County delivery:

• Website: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/
• Phone: (832) 416-2816
• Email: [email protected]
• Business hours: Monday-Thursday 10 AM-7 PM, Friday-Saturday 10 AM-10 PM, Sunday 10 AM-4 PM (Central Time)

When you order, specify you’re in Champaign County, Illinois for most accurate shipping estimates.

How the OilWell formulas connect to the evidence in this document

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in GENERAL KNOWLEDGE section. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene—is covered with preclinical and review-level evidence.

Formulas published later in this document are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to current evidence base. Where OilWell’s RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides source evaluation context—same peer-reviewed citations, same evidence-tier assessments, same cautious interpretation framework.

GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from same evidence standards applied to broader cannabinoid field. That is intentional. OilWell’s position—as stated by Colin Valencia in 2019—is that people deserve best possible version of information so they can give it fair shot and decide for themselves whether it is right or wrong for them. This document is research foundation for that position.

OilWell Cannabis is more than brand—it is promise to customers that it will always strive to deliver best, most thoughtful cannabis products available. OilWell is not here to follow trends. It is here to set them. And as company continues to grow, focus remains on maintaining same level of integrity, creativity, and commitment that has defined it from day Bentley got up, walked across room, and brought his ball to play.

For Champaign County residents, this means you’re partnering with company whose foundation is built on love, loss, scientific rigor, and unwavering commitment to transparency. Whether you’re in Urbana researching at university, in Champaign running business, or anywhere across Central Illinois dealing with health challenges, OilWell offers something rare: products backed by real story, real science, and real integrity.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK)—ABC affiliate serving fourth-largest city in United States—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during same period.

Features document consistent pattern. When ABC13 needed to explain new cannabis product to audience, it called Colin. When state agency reversed course on Delta-8 legality overnight, it called Colin. When sitting president announced marijuana pardons and station needed someone who had personally lived with cannabis conviction to put it in context, it called Colin. When station wanted to tell story of growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored report.

What follows is complete, chronological record of each feature—every quote preserved exactly as published, every contextual detail documented, every connection to broader OilWell story and mission noted, and full article content from each ABC13 report preserved for reference.

Feature: Texas CBD businesses booming as industry continues to evolve—September 15, 2019

Source: ABC13 Houston (KTRK)
Headline: “Texas CBD businesses booming as industry continues to evolve”
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019
Tags: Health & Fitness, Houston, Marijuana, U.S. & World, Texas News, Business
YouTube Clip: OilWell CBD Oil Houston ABC News KTRK Interview Clipped (54 seconds)

This is earliest documented ABC13 feature on OilWell—and origin point of foundational philosophy that drives everything in this document.

Full article content

HOUSTON, Texas (KTRK) — You can spot the signs in almost any neighborhood. CBD has turned into a booming business over the past few months, with entrepreneurs pitching the product for every member of the family, even the pets.

Amanda Field owns Republic Aerial Yoga on Houston Avenue in downtown. Her clients visit her studio for their health, to educate themselves, and to lessen their aches and pains.

“I’ve had people tell me that they’ve come to two classes and their back pain is gone.”
— Amanda Field, Republic Aerial Yoga owner

But for Field, it’s not just about yoga. Many of her clients combine the exercise with cannabidiol, a hemp-based product better known as CBD.

“It partners so well with yoga.”
— Amanda Field

Krystal Burns is one of those clients. She said she injured her back in an accident and had surgery. She said she was in constant pain and said doctors wanted to prescribe her opioids. Burns refused, and after learning about CBD from Field, she says she’s now a believer.

“I wouldn’t be able to function without it. It easily relaxes my muscles, it helps me sleep. I don’t have to worry about addiction.”
— Krystal Burns, CBD user and yoga client

Jim Bagley is another believer. He owns Linear Salon in the Heights. He says he and his wife use CBD and sell it in their shop.

“I was having trouble sleeping, restless in the mid-morning probably. I truly feel that there is benefits to it. I hope it’s not a trend. I think that the benefits I’ve received personally, hopefully I’ll be able to get my clients to enjoy the same benefits I’ve received.”
— Jim Bagley, Linear Salon owner

CBD use was in a legal, gray area in Texas until House Bill 1325, which Gov. Greg Abbott signed into law in June. The bill changed the legal definition of marijuana and hemp production in Texas. As a result, CBD as a business is booming. The product, however, cannot have .3 percent of THC, the chemical that makes you high.

That past summer, four local district attorneys announced they would not file criminal cases involving marijuana or cannabis unless testing proved the THC concentration was higher than .3 percent.

Dorral Marsenburg sells his Booman cannabis in a smokable form and says the industry is in its infancy in Texas.

“In a typical week, I’ll go through a half a pound selling grams. I say two years from now, it’ll be a multi-billion dollar operation. I honestly believe that because it’s 100 percent legal, and besides the THC, it’s healthy for you also.”
— Dorral Marsenburg, Booman cannabis

Colin Valencia, who runs OilWell CBD, a local wholesaler, says it’s an evolving industry.

“It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”
— Colin Valencia, OilWell CBD

The FDA is still examining the actual health benefits and ways to regulate the content of cannabis products. In May, it held its first ever CBD hearings and states it is committed to sound, science-based policy.

Related: New hemp law means no criminal charges for some pot possession cases, Harris County DA says | CBD Oil: What you need to know

Video Description: “CBD TAKEOVER: The industry continues to grow with entrepreneurs pitching the product for every member of the family, including pets!”

Analysis

That Colin quote—from 2019, years before formulas in this document were published—is seed of everything OilWell would become. Open-source formula publication, evidence-based research documentation, refusal to make unsupported claims: it all traces back to this principle. Video segment’s description noting CBD was being pitched “for every member of the family, including pets” is early indicator of broad-spectrum consumer education approach Colin would continue to build. Clipped version of Colin’s interview from this broadcast was separately uploaded to YouTube as standalone demonstration of OilWell’s media presence on major network affiliate.

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts—March 22, 2021

Source: ABC13 Houston (KTRK)
Headline: “Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts”
Reporter: Tom Abrahams
Published: Monday, March 22, 2021
Tags: Texas, Marijuana, Laws, Senate, Cannabis Watch

Full article content

HOUSTON, Texas (KTRK) — The proof is evident that decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. It’s a basis as to why there is a renewed push to decriminalize cannabis at the national level.

One entrepreneur is already coming up with a unique way to get cannabis directly to the customer.

It’s not a taco truck. In fact, Jonathan Pina’s concept for High Maintenance Edibles is not like any other mobile vendor you’ve likely seen.

“We partner with private companies, bars restaurants, parking lot owners and we show up at places around Houston and provide our products.”
— Jonathan Pina, High Maintenance Edibles

His concept got a lift from Oil Well. A company that specializes in hemp based products legal in Texas and run by owner Colin Valencia. He said the tide is turning and more and more people accept legitimate uses for cannabis based products. The stigma is slowly disappearing.

“People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”
— OilWell CBD’s Colin Valencia

It’s getting a step closer to both decriminalization and legalization. While Texas may be far from legal recreational use, Congress may make its own move.

This week, Schumer and Senators Corey Booker of New Jersey and Ron Wyden of Oregon announced forthcoming legislation on Capitol Hill.

“When states decriminalized or legalized, all the horrible stories that people said crime rates would go up, people’s drug use would go up, never materialized.”
— Senator Chuck Schumer

The three of them cited the failed war on drugs, that veterans and people of color are disproportionately punished for use with excessive fines or jail time. There are already 15 states that have passed ballot measures or have laws allowing recreational use.

“If people want to use it and it doesn’t do harm, just like Oregon showed, let them do it.”
— Senator Chuck Schumer

For those in the business and on its forefront in Texas, entrepreneurs like Pina believe it’s long overdue. But in Austin, they are not there yet. Despite loosening restrictions and a spate of bills this session, full legalization is not as likely as it might be in Washington.

Related: Texas lawmakers hope to expand medical marijuana programs this legislative session | Texas’ medical marijuana program is one of the most restrictive in the country

Video Description: Decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. He said there’s a renewed push to decriminalize marijuana at the national level, but how will this impact Texas?

Analysis

Tom Abrahams returned to OilWell for this feature, establishing Colin’s role not just as business operator but as ecosystem builder who helped other entrepreneurs like Jonathan Pina enter legal cannabis space. Colin’s therapy quote—”pain comes in a lot of different forms”—went deeper than any prior interview into therapeutic dimension, and national decriminalization context (Schumer, Booker, Wyden) positioned OilWell at intersection of Texas innovation and federal momentum.

Feature: What is Delta 8 THC and why is it considered legal weed in Texas—May 24, 2021

Source: ABC13 Houston (KTRK)
Headline: “What is Delta 8 THC and why is it considered ‘legal weed’ in Texas?”
Reporter: Steve Campion
Published: Monday, May 24, 2021
Tags: Society, Texas, Marijuana, Texas News, Smoking, Doctors, Illegal Drugs, Drugs
Note: Features 4 and 8 in original URL list share this same URL—this is one article.

Full article content

A lush green plant is creating buzz in Texas as the cannabis industry is booming, despite federal and state law banning marijuana.

The 2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of the psychoactive compound Delta 9 THC. That’s the THC typically found in pot which gives users a high. Entrepreneurs are now extracting any compound they want from the hemp plants and have narrowed in on Delta 8 THC. They’re making products including edibles, tinctures, and smokables with it. Delta 8 THC isn’t as strong as Delta 9 THC.

You’ll likely spot the Delta 8 products in stores around the Greater Houston like at HydroShack Hydroponics on West 20th Street in The Heights which sells Oilwell Cannabis products.

“Demand is like this,” . “People are grateful that we’re here and selling it. Very grateful. That’s the feeling I get.”
— Chris Powers, owner of HydroShack Hydroponics

Colin Valencia with Oilwell said the products offer therapeutic benefits at affordable prices. Valencia remained unabashed by his enthusiasm for them. He offered a pretty blunt explanation about how some might use Delta 8.

Steve Campion (ABC13): “Why would someone want to smoke that?”

Colin Valencia: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

“Delta 8 hasn’t been looked at, so we just don’t know. We’re gathering data now, so the more people who use, the more information we’ll have. You probably don’t want to be a guinea pig just yet. We know Delta 9 THC is habit forming. Delta 8 THC is likely to have that property as well. If you’re using it, you may find it’s harder to stop than you thought.”
— Dr. Michael Weaver, UTHealth/UT Physicians addictions specialist

ABC13 then asked him if he would advise anyone to take it.

“I think there is not enough information to say it’s good to try. The safest thing I can say is we don’t know enough about it to make a recommendation. Don’t try it until we know more.”
— Dr. Michael Weaver

Experts said using Delta 8 THC will likely lead to failed drug tests for employees.

Heather Fazio with Texans for Responsible Marijuana Policy told ABC13 some lawmakers already want to ban Delta 8 products in state. She said conversation should be on regulation, not prohibition.

“We’re seeing the market become innovative. Entrepreneurs getting creative with the ways they can abide by the law and still provide their customers with the product they would like. What we’re looking at here is simply the result of supply and demand. We know there is a demand for cannabis products in the state of Texas. Unfortunately, our state continues to deprive legitimate business owners of the opportunity to sell these products in a regulated way, products that are tested that are labeled appropriately.”
— Heather Fazio, Texans for Responsible Marijuana Policy

DEA Statement:

Delta 8 THC was added to the controlled substances list in August 2020 on an interim basis while pending final disposition. As DEA is currently undergoing the rulemaking process regarding the implementation of the Agriculture Improvement Act of 2018 – which includes the scope of regulatory controls over marijuana, tetrahydrocannabinols, and other marijuana-related constituents – we would be unable to comment on an any impact in legality of tetrahydrocannabinols, Delta 8 included, until the process is complete. We are in the process of reviewing thousands of comments and do not speculate on what could happen as a result.

Related: Texas’ medical cannabis program could expand under bill OK’d by House

Video Description: This lush green plant is creating buzz in Texas. ABC13 reporter Steve Campion investigated what it is, its effects on the body and whether or not it is legal in Texas.

Analysis

This investigative feature by Steve Campion became one of most widely referenced ABC13 cannabis segments. Exchange between Campion and Colin—”Maybe you want to get high”—became one of Colin’s most iconic media moments: radical honesty on mainstream television with expletive preserved by network. Piece balanced Colin’s unapologetic stance with Dr. Weaver’s medical caution and Heather Fazio’s regulatory advocacy, and full DEA statement documented federal ambiguity that allowed market to exist. This article was cross-referenced by ABC13 in multiple subsequent features and served as foundational explainer that later Delta-8 coverage built upon.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine—August 20, 2021

Source: ABC13 Houston (KTRK)
Headline: “Houston CBD shop giving away free products to those who get COVID vaccine”
Reporter: KTRK Staff
Published: Friday, August 20, 2021
Tags: Health & Fitness, Houston, COVID 19 Vaccine, Marijuana, Cannabis Watch, Vaccines, Coronavirus Pandemic, COVID 19 Pandemic, Pandemic, Texas News, Health Care

Full article content

HOUSTON, Texas (KTRK) — A Houston CBD shop is offering a unique incentive to get people vaccinated.

According to an Instagram post published on Wednesday, OilWell CBD, which specializes in hemp-derived CBD and THC products, said it wants to give away 1,000 pieces of product to those who get vaccinated after Aug. 18.

The company is offering to give away 1,000 special edition caviar pre-rolls, which according to its website, is a THC-infused product coated with oils and hash kief, a more refined form of cannabis. OilWell sells these items for $34.99, according to its website.

The company said you must provide proof of vaccination along with a photo ID.

The giveaway will take place starting Monday at noon at HydroShack Hydroponics on West 20th Street in The Heights, which sells OilWell products.

“We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
— OilWell Instagram post

The company later posted another Instagram post saying it’s been in contact with the city of Houston to help more people get vaccinated.

“[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”
— OilWell follow-up Instagram post

The 2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of the psychoactive compound Delta-9 THC. That’s the THC typically found in marijuana that gives users a high. Entrepreneurs are now extracting any compound they want from the hemp plants and have narrowed in on Delta-8 THC. Companies like OilWell are now making products such as edibles, tinctures, and smokables.

Note: The video above is from an ABC13 report published on May 24 in which we spoke with OilWell CBD about Delta-8 THC products and why it’s considered “legal weed” in Texas.

Video Description: This lush green plant is creating buzz in Texas. ABC13 reporter Steve Campion investigated what it is, its effects on the body and whether or not it is legal in Texas.

Analysis

This feature documented OilWell’s most significant community health initiative—approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) donated to encourage COVID-19 vaccination. Pre-rolls were collaboration product: The Game x OilWell Cannabis Delta 8 Caviar Comet Rock Pre-Rolls. Giveaway was hosted at same HydroShack Hydroponics retail partner featured in Delta-8 segment months earlier. OilWell’s coordination with city of Houston to amplify vaccination effort demonstrated that company’s community orientation was not hypothetical—when public health crisis required action, company committed real product and real coordination with city government, with no political strings attached.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality—October 19, 2021

Source: ABC13 Houston (KTRK)
Headline: “Texas’ ban over once legal hemp product, Delta 8, raises questions over legality”
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021
Tags: Politics, Houston, Marijuana, Texas News, Texas Politics, Illegal Drugs

Full article content

HOUSTON, Texas (KTRK) — Inside the Oil Well dispensary in southwest Houston, owner Colin Valencia said he has removed all of his Delta 8 products.

“It’s going to be a surprise to a lot of people.”
— Colin Valencia

It’s a surprise because when ABC13 met Valencia earlier this year, Delta 8 products were his best sellers.

“It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
— Colin Valencia

Delta 8 is a cannabinoid sold as edibles, tinctures, pills, topical ointment, you can smoke it and vape it. Most CBD dispensaries and vape stores sell it.

“We’ve heard of vets with PTSD who use these products for things like anxiety, dealing with stress and emotions. There’s also people who use these products for sleep regulation. Our association recently, during the state session, actually estimated that the Delta 8 market is around about $50 million in Texas.”
— Zachary Maxwell, Texas Hemp Growers

Delta 8 is derived from hemp cannabis. It took off after the 2018 Farm Bill legalized hemp production federally. It is a THC product and, up until last week, it was never explicitly listed on the state’s controlled substance list.

“A lot of the industry has been operating under the assumption that Delta 8 is legal or that it exists inside of this gray area, and unfortunately, as we are learning, this is not the case. These products have in fact been illegal since the beginning of this year.”
— Zachary Maxwell

On Oct. 15 the Texas Department of State Health Services posted an update on their Consumable Hemp Program page saying in part, “All other forms of THC, including Delta 8 in any concentration and Delta 9 exceeding 0.3%, are considered Schedule I controlled substances.”

“And if you’re caught with as much as a Delta 8 vape cartridge or even a package of gummies, you could be looking at a felony offense punishable up to two years in prison and a fine up as much as $10,000.”
— Zachary Maxwell

He says the state made no other formal notification to the more than 2,000 licensed CBD operators including Valencia, who has been trying to spread the word himself.

“So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
— Colin Valencia

ABC13 reached out to Texas DPS to find out if and how the state will enforce this-known ban. They were still awaiting a response.

ABC13 spoke with the Texas DSHS to ask about the updated verbiage on Delta 8. A spokesperson says Delta 8 has always been illegal because it is a THC cannabinoid. She could not speak to how the Delta 8 market was allowed to publicly blossom and thrive while being considered illegal. She told ABC13 that the hemp industry asked DSHS for clarification on its legality which prompted the announcement last Friday.

While both men worry for the small businesses who rely on Delta 8 products for the majority of sales, they remain optimistic about the future of cannabis in Texas.

“It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”
— Colin Valencia

Video Description: A cannabis businessman says Texas’ recent move on making hemp products illegal is “dangerous.”

Analysis

This feature captures defining moment in OilWell’s story. Just two months after COVID vaccine giveaway, legal landscape shifted dramatically overnight. Shelley Childers went directly to OilWell dispensary and found that Colin had already removed all Delta-8 products from shelves—proactively, before enforcement began, and before most of industry even knew change had happened. Colin had been trying to spread word himself to other operators who were unknowingly shipping what had overnight become Schedule I narcotics. Zachary Maxwell’s context—veterans with PTSD, $50 million Texas market, felony penalties for single vape cartridge—made stakes viscerally clear. Texas DSHS told ABC13 that Delta-8 “has always been illegal” but could not explain how market had been “allowed to publicly blossom and thrive while being considered illegal.” Willingness to absorb major revenue loss, act ethically ahead of enforcement, and position company as expert guide for industry in crisis rather than victim of regulation—that is OilWell’s character.

Feature: Biden marijuana pardon—experts weigh in on why Texas won’t see impact—October 7, 2022

Source: ABC13 Houston (KTRK)
Headline: “Experts weigh in on why Texas won’t see impact in accordance with Biden’s pardon announcement”
Reporter: Nick Natario
Published: Friday, October 7, 2022
Tags: Politics, Houston, Marijuana, Medical Marijuana, Legal, Pardon, Texas, Greg Abbott, Beto O’Rourke

Full article content

HOUSTON, Texas (KTRC) — President Joe Biden is planning to pardon thousands of Americans convicted of simple possession of marijuana, but Texas will not see much of an impact.

The owners of Oilwell Cannabis are preparing to debut their latest idea: A vending machine that will be filled with legal cannabidiol, or CBD, products.

The shop owner, Collin Valencia, has previously faced charges for marijuana possession.

“You face challenges with housing, loans, and banking, I mean with about everything.”
— Colin Valencia

Soon, select others won’t face those challenges after the president’s announcement.

“I would love to see people not get hurt for this anymore.”
— Colin Valencia

The pardon doesn’t impact Valencia. As legal expert Steve Shellist explains, this will only apply to certain federal convictions.

“If someone is currently stripped of rights via a state prosecution or a state conviction, they’re going to get no relief from this.”
— Steve Shellist, legal expert

He said a pardon allows people to carry a gun or avoid deportation.

“It reinstates rights that were stripped away, but it does not remove it from their record.”
— Steve Shellist

The pardon applies to about 6,500 people. Experts at Rice University said that there were 300,000 marijuana-related arrests at the state level last year. President Biden urged governors to do the same with state charges.

A spokesperson for Governor Greg Abbott sent ABC13 a statement that read:

“Texas is not in the habit of taking criminal justice advice from the leader of the defund police party and someone who has overseen a criminal justice system run amuck with cashless bail and a revolving door for violent criminals.”
— Governor Greg Abbott’s spokesperson

On social media, Abbott’s opponent Beto O’Rourke said, “When I’m governor, we will finally legalize marijuana in Texas and expunge the records of those arrested for marijuana possession.”

“Governors do not have the power to pass legislation unilaterally. It has to go through the Texas Legislature, and the Texas legislature for at least the next two or four years is going to have a Republican majority.”
— Mark Jones, Rice University political science professor

Don’t expect to see marijuana legalization in the upcoming session. However, it doesn’t mean the matter won’t be discussed.

“The most we’ll see in 2023 is decriminalizing marijuana and medical marijuana. We’re not going to see legalization. That’s for sure.”
— Mark Jones

Related: Biden pardons thousands convicted for ‘simple possession’ of marijuana

Video Description: There were 300,000 marijuana-related arrests last year in the state of Texas, but the pardon applies to about 6,500 people, a legal expert explained.

Analysis

This feature brought most personal dimension of Colin’s story into public view. Article opened with OilWell CBD vending machine debut—retail innovation extending product accessibility beyond traditional dispensary hours—and then revealed that Colin has previously faced charges for marijuana possession. That personal history transforms entire media record. Every feature, every quote about therapy, about education, about not selling snake oil—all carry additional weight when you understand person saying it has personally experienced consequences of cannabis criminalization. Political context (300,000 state arrests vs. 6,500 pardons, Abbott vs. O’Rourke, Mark Jones’s analysis) captured gap between federal gestures and Texas reality. Colin is not outside entrepreneur who saw business opportunity. He is someone who lived consequences and built legal business to prove industry could operate with integrity, transparency, and community benefit.

Feature: Marijuana industry getting creative as Texas laws continue to change—April 21, 2023

Source: ABC13 Houston (KTRK)
Headline: “‘I want it to be legalized’: Marijuana industry getting creative as Texas laws continue to change”
Reporter: Nick Natario
Published: Friday, April 21, 2023
Tags: Health & Fitness, Texas, Marijuana, Medical Marijuana, Texas News, Texas Politics

Full article content

HOUSTON, Texas (KTRK) — On April 20, some Texas lawmakers and those in the marijuana industry are celebrating as changes could be coming with the drug.

The cannabis industry has changed in Texas, and new laws have allowed those in the industry to get creative.

“I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
— Oilwell Cannabis owner Colin Valencia

Valencia grows something that looks like marijuana, but he says it’s not illegal. It’s hemp—a product the state allows and one that gives him the ability to create all kinds of products.

“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”
— Colin Valencia

As far as legal marijuana, it’s still restrictive in Texas. To use it, marijuana needs to be prescribed. There are currently around 50,000 Texans registered, but experts say only about 10,000 actively use medical marijuana.

“By comparison to Florida, which is two-thirds the size of Texas, they have 20 million people, and we have 30 million people, and they have 700,000 patients.”
— Nico Richardson, Texas Original CEO

But that number could change soon. Texas lawmakers are considering a bill (HB1805) to expand who could gain access.

“Would rather dramatically increase the size of the CUP. The largest constituency of patients not being treated with medical cannabis today is chronic pain.”
— Nico Richardson

The bill passed the House and is heading to the Senate. It would also change how the drug is dosed to line up with other medical treatments.

“If you were to treat a headache with 400 milligrams of Advil and there was a one percent concentration cap, you would be using 20 to 40 Advil pills every time you had a headache.”
— Nico Richardson

While it’s not legalization, in other states, it’s had an impact, especially with money. The Marijuana Policy Project said in 2021 alone, $3.7 billion was generated in taxes in the states where marijuana is legal.

The CDC urges caution, saying more studies need to be done because the drug could impact your brain, lungs, and unborn children.

Related: Expanded access to medical marijuana gains traction as Texas House advances bill | University of Houston survey shows most Texans would approve of marijuana legalization

Video Description: The growing marijuana industry in Texas could soon expand

Analysis

Most recent ABC13 feature, published day after 4/20, completes four-year arc. Natario showed Valencia growing hemp and explained it was legal. Colin’s “Renaissance” framing reframed present as opportunity rather than waiting. Nico Richardson’s comparison (Texas 10,000 active patients vs. Florida 700,000 with two-thirds population) and Advil analogy for dosing caps provided industry context. HB1805’s passage through House and $3.7 billion tax revenue figure from legal states gave story national scope. From September 2019 CBD business profile through Delta-8 boom and bust, COVID community initiative, personal revelation of cannabis conviction history, and now “Renaissance” framing—Colin Valencia’s media trajectory mirrors trajectory of legal cannabis in Texas itself.

Complete index of all Colin Valencia quotes across all ABC13 features

Chronological order:

September 15, 2019 (CBD Business Boom):

1. “It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

March 22, 2021 (Decriminalization/Jonathan Pina):
2. “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

May 24, 2021 (Delta-8 THC “Legal Weed”):
3. “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

August 20, 2021 (COVID Vaccine Giveaway):
4. “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
5. “[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”

October 19, 2021 (Delta-8 Ban):
6. “It’s going to be a surprise to a lot of people.”
7. “It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
8. “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
9. “It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”

October 7, 2022 (Biden Marijuana Pardon):
10. “You face challenges with housing, loans, and banking, I mean with about everything.”
11. “I would love to see people not get hurt for this anymore.”

April 21, 2023 (Texas Marijuana Laws 4/20):
12. “I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
13. “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

Key facts and details extracted from media record

About Colin Valencia and OilWell Cannabis:

• Colin Valencia is owner of OilWell Cannabis (also referred to as OilWell CBD in earlier articles)
• He has previously faced charges for marijuana possession (revealed in October 2022 Biden pardon feature)
• OilWell dispensary is located in southwest Houston
• OilWell specializes in hemp-derived CBD and THC products
• OilWell was described as local wholesaler in 2019 (earliest feature)
• By 2022, OilWell was preparing to debut CBD vending machine (Biden pardon feature)
• OilWell products were sold at HydroShack Hydroponics on West 20th Street in The Heights
• OilWell partnered with The Game on special edition Delta-8 caviar comet rock pre-rolls (COVID vaccine feature)
• OilWell gave lift to Jonathan Pina’s High Maintenance Edibles mobile vendor concept (decriminalization feature)
• OilWell gave away 1,000 special edition caviar pre-rolls (valued at $34.99 each = approximately $35,000 in product) to encourage COVID vaccination
• OilWell contacted city of Houston to help coordinate vaccination efforts
• Colin proactively removed all Delta-8 products from shelves when ban was announced and tried to spread word to other operators who were unknowingly shipping Schedule I narcotics

ABC13 reporters who covered OilWell:

1. Tom Abrahams—September 2019 and March 2021
2. Steve Campion—May 2021
3. KTRK Staff—August 2021
4. Shelley Childers—October 2021
5. Nick Natario—October 2022 and April 2023

Timeline of features (chronological):

1. September 15, 2019—CBD Business Boom
2. March 22, 2021—Decriminalization/Jonathan Pina
3. May 24, 2021—Delta-8 THC “Legal Weed”
4. August 20, 2021—COVID Vaccine Giveaway
5. October 19, 2021—Delta-8 Ban Impact
6. October 7, 2022—Biden Marijuana Pardon
7. April 21, 2023—Texas Marijuana Laws 4/20 Special

The through-line—what the media record reveals

Taken together, these seven ABC13 features and one YouTube clip tell story that no single article could capture on its own.

Consistency across years. Colin Valencia appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. Cannabis industry in Texas changed dramatically during those years—legal CBD went from gray area to booming business, Delta-8 went from unknown to $50 million market to Schedule I overnight, president pardoned federal marijuana convictions, and state legislators debated medical expansion. Through every shift, ABC13 returned to Colin as primary source.

Breadth of expertise. Features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range of topics across that many segments.

Community action. COVID vaccine giveaway—$35,000 in product, coordination with city government, no political strings—is documented evidence of community-first philosophy described in About OilWell section. So is Colin’s decision to proactively remove Delta-8 products and warn other operators before enforcement began.

Personal stakes. October 2022 revelation that Colin has personal marijuana conviction history transforms entire media record. Every feature—every quote about therapy, about education, about not selling snake oil—carries additional weight when you understand person saying it has personally experienced consequences of cannabis criminalization.

Evolution of language. In 2019, ABC13 called business “OilWell CBD, a local wholesaler.” By 2021, reports described OilWell Cannabis as dispensary and featured Colin as industry authority. By 2023, Colin was explaining industry dynamics and legal strategy on camera with confidence of sector leader. Media record tracks growth of both business and its founder’s public role.

These features are not marketing materials. They are independently produced, editorially controlled news segments from major-market ABC affiliate that repeatedly identified Colin Valencia as most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is kind of recognition that cannot be purchased—it can only be earned.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters here because evidence base is not evenly distributed. Of compounds listed in this document, CBD and delta-9 THC have strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

For Champaign County’s university community—professors, researchers, healthcare professionals—this methodology transparency is crucial. You can evaluate claims based on evidence tier.

Institutional baseline from NIH and related sources

• NCCIH states that strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• NCCIH emphasizes FDA has not approved cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns repeatedly highlighted by NIH and institutional sources include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

Cannabinoids

CBD

• Evidence profile: strongest human evidence in current formula set, especially when CBD is studied as purified product rather than as loose wellness ingredient [1]-[6].
• What is best supported: purified CBD has most credible human evidence in seizure disorders, and this is clearest major-example indication acknowledged by institutional and peer-reviewed literature [1][2].
• Anxiety research: 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported statistically significant anxiolytic signal, but authors stressed clinical sample remains limited and more trials needed before broad conclusions justified [3].
• Pain research: 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims [4].
• Sleep research: 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments [5].
• Safety and interaction concerns: 2023 systematic review and meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions as important considerations [1].
• Bottom line: CBD is most evidence-developed nonintoxicating cannabinoid in this file, but even here, strong evidence is concentrated in few specific indications rather than broad, generalized wellness claims often seen in marketing [1]-[6].

CBG

• Evidence profile: mostly review-level and preclinical; human evidence remains sparse [7][8].
• Pharmacology: CBG is biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, making it mechanistically interesting but not yet clinically established [7].
• Potential research areas: published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].
• Caution: key point from 2021 pharmacology review is that CBG is already being sold commercially while evidence base remains thin, which means claims frequently outrun science [7].
• Bottom line: CBG is serious research topic, but at present it should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic cannabinoid [7][8].

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is partial CB1 agonist with cannabimimetic activity in animals and humans, but appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity [9].
• Public-health literature: 2023 scoping review found much of delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].
• Manufacturing context: recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter [11].
• Bottom line: delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa

• Evidence profile: important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].
• What it is: THCa is acidic precursor of THC and may represent very large share of THC-related content in raw plant material. Key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing [12].
• Psychoactivity: major review source stresses that THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in its acidic form and is not substantially decarboxylated [12].
• Research status: in vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].
• Bottom line: THCa is best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC [12].

Delta-9 THC

• Evidence profile: strongest human evidence of psychoactive cannabinoids listed here, but also clearest adverse-effect burden [1][13]-[15].
• What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while still stressing that many other uses remain uncertain or early-stage [1].
• Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].
• Pharmacokinetics and onset: classic pharmacokinetic review literature remains useful here: inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15-30 minutes, and tapers over few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk [14].
• Mental-health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings [15].
• Broader safety: institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products [1][14][15].
• Bottom line: delta-9 THC has legitimate therapeutic relevance in some settings, but it also carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN

• Evidence profile: weak human evidence; marketing has clearly moved ahead of data [12][16][17].
• What it is often marketed for: sleep and sedation. That reputation is widespread, but clinical support is far thinner than market suggests [16][17].
• Best direct review for sleep claim: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].
• Broader sleep literature: 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match scale of real-world use, and need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].
• Bottom line: CBN is one of clearest examples in this field where cultural reputation is stronger than current clinical evidence base [16][17].

CBC

• Evidence profile: emerging, intriguing, and still overwhelmingly preclinical or review-based [18][19].
• Pharmacology and therapeutic interest: 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].
• What older literature shows: review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].
• Safety caution: 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not in category of already-validated clinical actives [18][19].

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

For Champaign County’s UIUC research community, this conservative approach to terpene claims is exactly what distinguishes credible science from marketing hype.

Limonene

• Evidence profile: largely review and preclinical, with useful safety literature [20]-[22].
• Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but overwhelming share of those claims comes from nonhuman or non-cannabis literature [21].
• Safety note: limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature [22].
• Bottom line: limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene

• Evidence profile: mostly preclinical, with very limited human evidence [20][23].
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking [23].
• Interpretation caution: myrcene is often invoked in consumer language as if it were proven sedating terpene that explains couch-lock or sleep effects. That is stronger claim than human evidence currently supports [20][23].
• Bottom line: myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene

• Evidence profile: among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].
• Research themes: anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in review literature, but human clinical confirmation remains limited [24].
• Bottom line: beta-caryophyllene is arguably strongest candidate for terpene with cannabinoid-system significance, but it still should not be described as clinically proven for outcomes commonly attributed to it [24].

Pinene

• Evidence profile: promising preclinical literature, weak human clinical confirmation [20][25].
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking [25].
• Interpretation caution: claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

• Evidence profile: similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research summary: linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing lack of robust human trials [25].
• Additional literature: separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26].
• Safety note: as with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].
• Bottom line: linalool is scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

• Evidence profile: translationally interesting, but still early [20][27].
• Scoping-review findings: 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Interpretation caution: those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
• Bottom line: humulene is one of more interesting terpene research targets in this list, but it remains far from clinically settled [27].

Terpinolene

• Evidence profile: one of least clinically characterized terpenes in this file [20][28].
• Systematic-review findings: 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has range of reported biological effects but that evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].
• Interpretation caution: even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].
• Bottom line: terpinolene is biologically interesting, but among listed terpenes it remains especially underdeveloped clinically [20][28].

Research limits and interpretation

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
• For THCa in particular, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements to avoid

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: myrcene is proven human sedative that reliably explains couch-lock.
  More accurate: myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].
• Overstatement: terpenes in general have proven entourage effects in patients.
  More accurate: entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].
• Overstatement: delta-8 THC is safe because it is hemp-derived.
  More accurate: delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical takeaways for formulas in this document

• Most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• Listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RSO SUBLINGUAL OIL FORMULA

Price: $129.99

Total Cannabinoids: 16,590 mg in 30 mL bottle (553 mg/mL)

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg

Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)

Base: Organic MCT oil

Dosing: Graduated dropper with 0.1 mL increments

Pharmacokinetics:

• Onset: 15-45 minutes
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%

Doses per bottle: 40-60 depending on serving size

Legal status: Farm Bill compliant (<0.3% delta-9 THC)

Shipping to Champaign County: USPS Priority Mail (2-3 days) or FedEx/UPS Ground (3-5 days)

How to order: https://oilwellcbd.com/product/rick-simpson-oil-rso-sublingual-oil/ or call (832) 416-2816

RSO VAPE CARTRIDGE FORMULA

Price: $49.99

Total Cannabinoids: 900+ mg in 1-gram cartridge

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

Live Terpenes: 5%+ (same seven-terpene profile as sublingual oil)

Compatibility: 510-thread universal battery

Pharmacokinetics:

• Onset: 1-2 minutes
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%

Activation: Auto-decarboxylation at 400-450°F vaporization temperature

Legal status: Farm Bill compliant

Shipping to Champaign County: Same nationwide shipping options as sublingual oil

How to order: https://oilwellcbd.com/product/1-gram-rick-simpson-oil-rso-vape/ or call (832) 416-2816

TERPENE PROFILE (BOTH PRODUCTS)

Our seven-terpene profile is identical across both RSO Sublingual Oil and RSO Vape Cartridge, providing consistent aromatic and potential entourage-effect benefits:

• Limonene: Citrus-bright aroma, potential mood-supporting properties [20]-[22]
• Myrcene: Earthy notes, commonly associated with relaxation (though human evidence limited) [20][23]
• Caryophyllene (β-caryophyllene): Pepper/spice aroma, selective CB2 agonist with anti-inflammatory potential [24]
• Pinene: Forest-fresh scent, potential cognitive support (preclinical) [20][25]
• Linalool: Floral, lavender notes, stress-support potential (preclinical) [20][22][25][26]
• Humulene: Earthy, woody aroma, anti-inflammatory potential (preclinical) [20][27]
• Terpinolene: Piney, fruity, sparkling aroma, least clinically characterized but biologically interesting [20][28]

For Champaign County residents familiar with local flora—whether it’s the pine forests near Lake of the Woods, the lavender fields some local growers cultivate, or the citrus notes in summer farmers market produce—these terpenes connect to familiar scents and experiences.

FINAL THOUGHTS FOR CHAMPAIGN COUNTY

We started this guide by telling you we wouldn’t sell you snake oil. We meant it. Everything you’ve just read—the complete Rick Simpson story with all its limitations, the full evidence profiles for seven cannabinoids and seven terpenes, the personal story of Bentley and Colin’s own recovery, the seven ABC13 features documenting years of consistent community engagement, the exact formulas with every milligram, the dosing protocols, the safety warnings, the legal framework—this is what transparency looks like.

For Champaign County residents, whether you’re in Urbana, Champaign, Savoy, Mahomet, Rantoul, St. Joseph, or anywhere in between, you now have the most comprehensive RSO education available anywhere. You know exactly what’s in our products, exactly what the science says (and doesn’t say), exactly how to use them safely, and exactly how to get them delivered to your door.

We’re not here to tell you RSO will cure cancer. We’re here to tell you that cannabinoids have interesting preclinical evidence, that some human trials show promise for specific symptoms, that traditional RSO had serious limitations, and that our modern formulation addresses those limitations while preserving the core principle: patients deserve access and control.

We understand that Champaign County values education, evidence, and straight talk. The University of Illinois culture, the agricultural pragmatism, the healthcare excellence at Carle and OSF—all of these shape a community that doesn’t fall for hype but will embrace real solutions when presented with honesty.

If you’re dealing with chronic pain and conventional treatments have failed, if you’re supporting a loved one through cancer treatment and looking for adjunctive options, if you’re a veteran with PTSD who has tried everything else, if you’re simply cannabis-curious and want to understand what RSO actually is—we’re here for you.

Our products ship discreetly to Champaign County. Our formulas are open-source. Our founder has lived the struggles you may be facing. Our media record shows years of consistent, honest advocacy. Our evidence review demonstrates we don’t overstate what science supports.

This is the OilWell difference. This is what real cannabis medicine looks like in 2025. And we’re proud to serve Champaign County with the same integrity that’s defined us since the day Bentley got up and brought his ball to play.

Order today: https://oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

Questions for Champaign County residents: (832) 416-2816

Email: [email protected]

Address: 810 Richmond Avenue, Houston, TX 77006 (Montrose neighborhood)

Hours: Monday-Thursday 10 AM-7 PM, Friday-Saturday 10 AM-10 PM, Sunday 10 AM-4 PM (Central Time)

We ship to Champaign County daily. Your order will arrive in 2-5 business days with full documentation, lab testing results, and our commitment to your health journey.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. Must be 21+ to purchase. Buyer assumes all legal responsibility for compliance with local laws.